MAM
UTMD icon

Martingale Asset Management’s Utah Medical Products UTMD Stock Holding History

Martingale Asset Management’s Portfolio UTMD Stock Details UTMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$242K Buy
3,911
+200
+5% +$12.6K 0.01% 758
2025
Q4 		$208K Sell
3,711
-3
-0.1% -$174 0.01% 750
2025
Q3 		$234K Hold
3,714
– – 0.01% 725
2025
Q2 		$211K Sell
3,714
-353
-9% -$19.2K 0.01% 751
2025
Q1 		$228K Buy
4,067
+101
+3% +$6.05K 0.01% 724
2024
Q4 		$244K Sell
3,966
-2
-0.1% -$129 0.01% 720
2024
Q3 		$266K Buy
3,968
+201
+5% +$13.6K 0.01% 726
2024
Q2 		$252K Buy
3,767
+100
+3% +$6.81K 0.01% 719
2024
Q1 		$261K Buy
3,667
+301
+9% +$22.6K 0.01% 729
2023
Q4 		$283K Hold
3,366
– – 0.01% 713
2023
Q3 		$289K Buy
3,366
+5
+0.1% +$461 0.01% 692
2023
Q2 		$313K Buy
3,361
+2
+0.1% +$188 0.01% 690
2023
Q1 		$318K Hold
3,359
– – 0.01% 699
2022
Q4 		$338K Sell
3,359
-19
-0.6% -$1.73K 0.01% 699
2022
Q3 		$289K Buy
3,378
+70
+2% +$6.18K 0.01% 715
2022
Q2 		$285K Buy
3,308
+2
+0.1% +$171 0.01% 742
2022
Q1 		$298K Sell
3,306
-300
-8% -$27.6K ﹤0.01% 725
2021
Q4 		$361K Hold
3,606
– – ﹤0.01% 703
2021
Q3 		$336K Buy
+3,606
New +$319K ﹤0.01% 734
2020
Q4 		– Sell
-10,802
Closed -$863K – 1046
2020
Q3 		$863K Sell
10,802
-13,200
-55% -$1.1M 0.01% 671
2020
Q2 		$2.13M Buy
24,002
+300
+1% +$26.9K 0.03% 511
2020
Q1 		$2.23M Buy
23,702
+400
+2% +$37.2K 0.03% 464
2019
Q4 		$2.52M Buy
23,302
+200
+0.9% +$20.3K 0.03% 542
2019
Q3 		$2.21M Buy
23,102
+600
+3% +$55.8K 0.02% 565
2019
Q2 		$2.15M Buy
22,502
+400
+2% +$33.7K 0.02% 575
2019
Q1 		$1.95M Buy
22,102
+3,100
+16% +$273K 0.02% 606
2018
Q4 		$1.58M Buy
19,002
+1,700
+10% +$150K 0.02% 600
2018
Q3 		$1.63M Buy
17,302
+100
+0.6% +$9.55K 0.02% 600
2018
Q2 		$1.9M Hold
17,202
– – 0.02% 559
2018
Q1 		$1.7M Sell
17,202
-200
-1% -$17.8K 0.02% 574
2017
Q4 		$1.42M Buy
17,402
+201
+1% +$15.7K 0.02% 630
2017
Q3 		$1.27M Buy
17,201
+6,300
+58% +$453K 0.02% 676
2017
Q2 		$790K Buy
10,901
+2,700
+33% +$178K 0.01% 756
2017
Q1 		$511K Sell
8,201
-1,400
-15% -$88.1K 0.01% 816
2016
Q4 		$699K Buy
9,601
+1,400
+17% +$91K 0.01% 783
2016
Q3 		$491K Buy
8,201
+4,300
+110% +$274K 0.01% 812
2016
Q2 		$246K Buy
3,901
+400
+11% +$25.8K ﹤0.01% 780
2016
Q1 		$219K Buy
+3,501
New +$206K ﹤0.01% 769

Other funds holding UTMD

BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MA
Minerva Advisors Bala Cynwyd, Pennsylvania $155M AUM 35.49% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Martingale Asset Management's UTMD Position: Q1 2026 in Review

Martingale Asset Management increased its Utah Medical Products (UTMD) stake by 5.4% in Q1 2026, buying an estimated $12.6K and bringing the position to 3,911 shares worth $242K. The position accounts for 0.01% of the portfolio, ranked #758.

Martingale Asset Management first reported a position in UTMD in Q1 2016 and has held it in 38 quarters since. The position peaked at $2.52M in Q4 2019. 119 funds tracked by Wall St. Rank hold UTMD as of Q1 2026.

  • Martingale Asset Management held 3,911 shares of Utah Medical Products worth $242K as of Q1 2026.
  • Martingale Asset Management bought 200 Utah Medical Products shares in Q1 2026, an estimated $12.6K.
  • Utah Medical Products made up 0.01% of Martingale Asset Management's portfolio in Q1 2026, its #758 holding.
  • Martingale Asset Management first reported a position in Utah Medical Products in Q1 2016 and has held it in 38 quarters since.
  • Martingale Asset Management's Utah Medical Products position peaked at $2.52M in Q4 2019.
  • 119 funds tracked by Wall St. Rank held Utah Medical Products as of Q1 2026.

Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.